517 lines
32 KiB
HTML
517 lines
32 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="zh-CN" data-theme="night">
|
||
<head>
|
||
<meta charset="UTF-8">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||
<title>深度投研报告：干细胞</title>
|
||
<script src="https://cdn.jsdelivr.net/npm/alpinejs@3.13.3/dist/cdn.min.js" defer></script>
|
||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.7.2/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||
<script src="https://cdn.tailwindcss.com"></script>
|
||
<script src="https://cdn.jsdelivr.net/npm/echarts@5.5.0/dist/echarts.min.js"></script>
|
||
<style>
|
||
/* Custom Styles for Sci-Fi FUI Aesthetic */
|
||
@import url('https://fonts.googleapis.com/css2?family=Sora:wght@300;400;600;700&display=swap');
|
||
|
||
body {
|
||
font-family: 'Sora', sans-serif;
|
||
background-color: #000005;
|
||
color: #E0E0E0;
|
||
overflow-x: hidden;
|
||
position: relative;
|
||
}
|
||
|
||
/* James Turrell inspired background glows */
|
||
body::before {
|
||
content: '';
|
||
position: fixed;
|
||
top: -20%;
|
||
left: -20%;
|
||
width: 80%;
|
||
height: 80%;
|
||
background: radial-gradient(circle, rgba(0, 150, 255, 0.15) 0%, rgba(0, 150, 255, 0) 60%);
|
||
animation: pulse-glow-blue 15s infinite ease-in-out;
|
||
z-index: 0;
|
||
}
|
||
|
||
body::after {
|
||
content: '';
|
||
position: fixed;
|
||
bottom: -30%;
|
||
right: -30%;
|
||
width: 100%;
|
||
height: 100%;
|
||
background: radial-gradient(circle, rgba(190, 70, 255, 0.1) 0%, rgba(190, 70, 255, 0) 55%);
|
||
animation: pulse-glow-purple 20s infinite ease-in-out;
|
||
z-index: 0;
|
||
}
|
||
|
||
@keyframes pulse-glow-blue {
|
||
0%, 100% { transform: scale(1) translate(0, 0); opacity: 0.8; }
|
||
50% { transform: scale(1.2) translate(10%, -10%); opacity: 1; }
|
||
}
|
||
|
||
@keyframes pulse-glow-purple {
|
||
0%, 100% { transform: scale(1) translate(0, 0); opacity: 0.7; }
|
||
50% { transform: scale(1.1) translate(-5%, 5%); opacity: 0.9; }
|
||
}
|
||
|
||
/* Glassmorphism Card Style */
|
||
.glass-card {
|
||
background: rgba(10, 10, 20, 0.4);
|
||
backdrop-filter: blur(20px);
|
||
-webkit-backdrop-filter: blur(20px);
|
||
border: 1px solid rgba(255, 255, 255, 0.1);
|
||
border-radius: 1.5rem; /* 24px */
|
||
box-shadow: 0 8px 32px 0 rgba(0, 0, 0, 0.37);
|
||
transition: all 0.3s ease;
|
||
}
|
||
|
||
.glass-card:hover {
|
||
background: rgba(15, 15, 25, 0.5);
|
||
border: 1px solid rgba(255, 255, 255, 0.2);
|
||
transform: translateY(-5px);
|
||
}
|
||
|
||
.main-container {
|
||
position: relative;
|
||
z-index: 1;
|
||
}
|
||
|
||
/* Custom Scrollbar */
|
||
::-webkit-scrollbar {
|
||
width: 8px;
|
||
}
|
||
::-webkit-scrollbar-track {
|
||
background: rgba(255, 255, 255, 0.05);
|
||
}
|
||
::-webkit-scrollbar-thumb {
|
||
background: rgba(0, 190, 255, 0.5);
|
||
border-radius: 4px;
|
||
}
|
||
::-webkit-scrollbar-thumb:hover {
|
||
background: rgba(0, 190, 255, 0.8);
|
||
}
|
||
|
||
h1, h2, h3, h4 {
|
||
text-shadow: 0 0 10px rgba(0, 191, 255, 0.3);
|
||
}
|
||
|
||
.timeline {
|
||
position: relative;
|
||
padding-left: 2.5rem;
|
||
}
|
||
.timeline::before {
|
||
content: '';
|
||
position: absolute;
|
||
left: 0;
|
||
top: 0;
|
||
bottom: 0;
|
||
width: 2px;
|
||
background-image: linear-gradient(to bottom, rgba(0, 191, 255, 0), rgba(0, 191, 255, 0.8), rgba(0, 191, 255, 0));
|
||
}
|
||
.timeline-item {
|
||
position: relative;
|
||
}
|
||
.timeline-item::before {
|
||
content: '';
|
||
position: absolute;
|
||
left: -2.5rem;
|
||
top: 0.5rem;
|
||
width: 1rem;
|
||
height: 1rem;
|
||
border-radius: 50%;
|
||
background-color: #00BFFF;
|
||
border: 3px solid rgba(0, 191, 255, 0.3);
|
||
box-shadow: 0 0 15px #00BFFF;
|
||
}
|
||
|
||
.table thead th {
|
||
background-color: rgba(0, 191, 255, 0.1);
|
||
color: #00BFFF;
|
||
border-bottom: 2px solid rgba(0, 191, 255, 0.3);
|
||
}
|
||
.table tbody tr {
|
||
border-bottom-color: rgba(255, 255, 255, 0.1);
|
||
}
|
||
.table tbody tr:hover {
|
||
background-color: rgba(0, 191, 255, 0.05);
|
||
}
|
||
|
||
</style>
|
||
</head>
|
||
<body class="min-h-screen p-4 sm:p-6 lg:p-8">
|
||
<div class="main-container max-w-7xl mx-auto">
|
||
|
||
<!-- Header -->
|
||
<header class="text-center mb-12">
|
||
<h1 class="text-4xl sm:text-5xl lg:text-6xl font-bold tracking-wider text-white">
|
||
干细胞 <span class="text-cyan-400">|</span> STEM CELL
|
||
</h1>
|
||
<p class="mt-4 text-lg text-gray-400">深度投研报告 | Deep Dive Research Report</p>
|
||
<p class="mt-2 text-xs text-gray-500">北京价值前沿科技有限公司 AI投研agent：“价小前投研” 进行投研呈现，本报告为AI合成数据，投资需谨慎。</p>
|
||
</header>
|
||
|
||
<!-- Bento Grid Layout -->
|
||
<div class="grid grid-cols-12 gap-6">
|
||
|
||
<!-- Insight: Main Column -->
|
||
<div class="col-span-12 lg:col-span-8 space-y-6">
|
||
<div class="glass-card p-6 h-full">
|
||
<h2 class="text-2xl font-bold text-cyan-400 mb-4 border-b border-cyan-400/20 pb-2">概念Insight：干细胞</h2>
|
||
|
||
<div class="space-y-4 text-gray-300 text-sm leading-relaxed">
|
||
<h3 class="font-semibold text-lg text-white">0. 概念事件</h3>
|
||
<p>干细胞概念在2024年末至2025年初迎来历史性转折点，标志着行业从漫长的研发期正式迈入商业化元年。这一系列事件由国内外监管的里程碑式突破所引爆，并迅速传导至资本市场。</p>
|
||
<ul class="list-disc list-inside space-y-1 pl-2 text-gray-400">
|
||
<li><strong class="text-cyan-400">2024年12月18日:</strong> 美国FDA批准Mesoblast公司的Ryoncil上市，成为全球首款获FDA批准的“现货型”间充质干细胞（MSC）疗法。</li>
|
||
<li><strong class="text-cyan-400">2025年1月2日:</strong> 中国NMPA附条件批准铂生卓越的艾米迈托赛注射液上市，标志着中国首款干细胞治疗药品诞生。</li>
|
||
<li><strong class="text-cyan-400">2025年Q2:</strong> 国内首款获批干细胞药物开出首张处方，商业化进程正式启动。</li>
|
||
</ul>
|
||
|
||
<h3 class="font-semibold text-lg text-white mt-4">1. 核心观点摘要</h3>
|
||
<p>干细胞行业正处在一个由政策明朗化和技术商业化共同驱动的<strong class="text-cyan-400">历史性拐点</strong>。随着中美两国相继批准首款MSC药物上市，行业已从纯粹的“概念叙事”阶段，正式迈入以<strong class="text-cyan-400">临床数据和商业化落地为核心驱动力</strong>的基本面验证新周期。未来，行业的增长潜力将取决于核心适应症的临床突破、成本控制下的商业化推广、以及下一代技术（如iPSC）的迭代。</p>
|
||
|
||
<h3 class="font-semibold text-lg text-white mt-4">2. 概念的核心逻辑与市场认知分析</h3>
|
||
<div class="space-y-2">
|
||
<p><strong class="text-white">核心驱动力:</strong></p>
|
||
<ul class="list-decimal list-inside pl-2 text-gray-400 space-y-1">
|
||
<li><strong class="text-cyan-500">政策驱动的合规化与加速：</strong>监管机构明确“药品”监管路径，为行业发展扫清障碍，IND申请数量爆发式增长。</li>
|
||
<li><strong class="text-cyan-500">技术成熟与里程碑式突破：</strong>中美相继批准MSC药物，强力验证技术路线的可行性。</li>
|
||
<li><strong class="text-cyan-500">巨大的未满足临床需求：</strong>主攻脑卒中、心衰、糖尿病等传统药物难以治愈的退行性疾病，市场空间广阔。</li>
|
||
</ul>
|
||
<p><strong class="text-white">预期差分析:</strong></p>
|
||
<ul class="list-decimal list-inside pl-2 text-gray-400 space-y-1">
|
||
<li><strong class="text-fuchsia-400">“万能神药”叙事 vs. 商业化初期现实：</strong>首批获批适应症（aGVHD）市场较小，是监管路径的“敲门砖”，大适应症开发难度高、周期长，市场可能低估了研发失败率。</li>
|
||
<li><strong class="text-fuchsia-400">上游存储业务 vs. 下游创新药业务：</strong>细胞存储是成熟现金牛业务，但增长空间有限；创新药研发是高风险高回报的成长业务，估值逻辑完全不同。</li>
|
||
<li><strong class="text-fuchsia-400">技术路线的迭代风险：</strong>市场焦点集中于MSC技术，但iPSC技术在糖尿病等领域取得突破，可能对现有主流技术构成颠覆性挑战。</li>
|
||
</ul>
|
||
</div>
|
||
|
||
<h3 class="font-semibold text-lg text-white mt-4">3. 关键催化剂与未来发展路径</h3>
|
||
<div class="space-y-2">
|
||
<p><strong class="text-white">近期催化剂 (未来3-6个月):</strong></p>
|
||
<ul class="list-disc list-inside pl-2 text-gray-400 space-y-1">
|
||
<li><strong class="text-cyan-400">关键临床数据读出：</strong>重点关注中源协和的牙周炎II期数据（预计2025年中），若数据积极将极大提振板块。</li>
|
||
<li><strong class="text-cyan-400">核心管线进展：</strong>九芝堂的缺血性脑卒中和肺泡蛋白沉积症（aPAP）II期进展。</li>
|
||
<li><strong class="text-cyan-400">支付政策突破：</strong>海南博鳌试点收费（3-15万元/疗程），后续商业险或地方医保的覆盖是重大利好。</li>
|
||
</ul>
|
||
<p><strong class="text-white">长期发展路径:</strong></p>
|
||
<ol class="list-decimal list-inside pl-2 text-gray-400 space-y-1">
|
||
<li><strong class="text-white">近期 (1-2年):</strong> MSC技术为主导，在GVHD、骨关节炎等领域实现多点商业化突破。</li>
|
||
<li><strong class="text-white">中期 (3-5年):</strong> 向脑卒中、心衰等大适应症渗透，生产工艺优化推动成本下降。</li>
|
||
<li><strong class="text-white">远期 (5-10年):</strong> iPSC等下一代技术走向成熟，实现“现货”通用型细胞药物，成为再生医学主流手段。</li>
|
||
</ol>
|
||
</div>
|
||
|
||
<h3 class="font-semibold text-lg text-white mt-4">4. 产业链与核心公司深度剖析</h3>
|
||
<p>产业链分为上游（设备耗材、细胞存储）、中游（技术研发、CDMO）和下游（临床应用）。核心玩家逻辑各异：</p>
|
||
<ul class="list-disc list-inside space-y-2 pl-2">
|
||
<li><strong>中源协和 (600645):</strong> 平台型龙头，"细胞存储(现金牛) + 创新药(增长引擎)"双轮驱动。牙周炎管线是近期最大看点。</li>
|
||
<li><strong>九芝堂 (000989):</strong> 专注型创新者，聚焦骨髓MSC，拥有国内独家的脑卒中、aPAP管线，壁垒高。</li>
|
||
<li><strong>天士力 (600535):</strong> 国际合作探路者，与全球龙头Mesoblast合作切入心衰，但合作产品曾在美国III期失败，风险与机遇并存。</li>
|
||
<li><strong>南华生物 / 南京新百:</strong> 存储业务巨头，拥有区域垄断牌照，但存储市场趋于饱和，面临iPSC通用细胞库的潜在挑战。</li>
|
||
</ul>
|
||
|
||
<h3 class="font-semibold text-lg text-white mt-4">5. 潜在风险与挑战</h3>
|
||
<ul class="list-disc list-inside space-y-2 pl-2 text-gray-400">
|
||
<li><strong class="text-red-400">技术风险:</strong> 疗效不确定性（临床失败风险）、iPSC安全性（致瘤风险）、质量控制与标准化难度大。</li>
|
||
<li><strong class="text-yellow-400">商业化风险:</strong> 成本与定价高昂、支付体系不完善、市场接受度与特殊冷链运输构成挑战。</li>
|
||
<li><strong class="text-orange-400">政策与竞争风险:</strong> 监管政策变动、热门适应症（如骨关节炎）同质化竞争激烈。</li>
|
||
</ul>
|
||
|
||
<h3 class="font-semibold text-lg text-white mt-4">6. 综合结论与投资启示</h3>
|
||
<p>干细胞行业已明确进入由<strong class="text-cyan-400">基本面驱动的成长初期</strong>。市场的焦点将转向能率先拿出说服力临床数据并成功商业化的公司。最具投资价值的细分环节：</p>
|
||
<ol class="list-decimal list-inside pl-2 text-gray-400 space-y-1">
|
||
<li><strong class="text-white">短期 (1-3年):</strong> 拥有进入临床II/III期、市场空间大且竞争格局好的创新药研发企业（如中源协和、九芝堂）。</li>
|
||
<li><strong class="text-white">中期 (3-5年):</strong> 具备平台型技术优势（如3D自动化培养降本）或在iPSC技术布局领先的公司。</li>
|
||
<li><strong class="text-white">稳健型:</strong> 上游的设备和耗材供应商（“卖铲人”逻辑），风险相对分散。</li>
|
||
</ol>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Side Column -->
|
||
<div class="col-span-12 lg:col-span-4 space-y-6">
|
||
|
||
<!-- Market Size -->
|
||
<div class="glass-card p-6">
|
||
<h3 class="text-xl font-bold text-cyan-400 mb-4">市场规模预测 | Market Projection</h3>
|
||
<div id="marketChart" style="width: 100%; height: 250px;"></div>
|
||
<p class="text-xs text-gray-400 mt-2">数据来源：Market.US, 前瞻产业研究院。全球市场CAGR 14%。</p>
|
||
</div>
|
||
|
||
<!-- Catalysts Timeline -->
|
||
<div class="glass-card p-6">
|
||
<h3 class="text-xl font-bold text-cyan-400 mb-6">关键催化剂 | Key Catalysts</h3>
|
||
<div class="timeline space-y-6">
|
||
<div class="timeline-item">
|
||
<p class="font-semibold text-white">2024.12 FDA批准全球首款MSC药物</p>
|
||
<p class="text-xs text-gray-400">Mesoblast的Ryoncil获批，引爆全球行业信心。</p>
|
||
</div>
|
||
<div class="timeline-item">
|
||
<p class="font-semibold text-white">2025.01 NMPA批准中国首款干细胞药</p>
|
||
<p class="text-xs text-gray-400">铂生卓越的艾米迈托赛注射液获批，开启商业化元年。</p>
|
||
</div>
|
||
<div class="timeline-item">
|
||
<p class="font-semibold text-white">2025年中 关键数据读出</p>
|
||
<p class="text-xs text-gray-400">中源协和牙周炎II期数据公布，市场高度关注。</p>
|
||
</div>
|
||
<div class="timeline-item">
|
||
<p class="font-semibold text-white">2026年 (预期)</p>
|
||
<p class="text-xs text-gray-400">九芝堂aPAP适应症有望通过附条件上市通道申报。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Highlights: Policy & Tech -->
|
||
<div class="glass-card p-6" x-data="{ tab: 'policy' }">
|
||
<div class="flex border-b border-cyan-400/20 mb-4">
|
||
<button @click="tab = 'policy'" :class="{'border-cyan-400 text-cyan-400': tab === 'policy', 'border-transparent text-gray-400': tab !== 'policy'}" class="flex-1 py-2 border-b-2 font-semibold transition">政策里程碑</button>
|
||
<button @click="tab = 'tech'" :class="{'border-fuchsia-400 text-fuchsia-400': tab === 'tech', 'border-transparent text-gray-400': tab !== 'tech'}" class="flex-1 py-2 border-b-2 font-semibold transition">技术突破</button>
|
||
</div>
|
||
<div x-show="tab === 'policy'" class="text-sm space-y-2 text-gray-300">
|
||
<p>✓ 全国首款干细胞药品 <span class="badge badge-outline badge-info">艾米迈托赛注射液</span> 获批</p>
|
||
<p>✓ 全国首张干细胞 <span class="badge badge-outline badge-info">《生产许可证》</span> 核发</p>
|
||
<p>✓ CDE出台 <span class="badge badge-outline badge-info">《人源干细胞产品非临床研究技术指导原则》</span></p>
|
||
<p>✓ 海南、上海等地积极推进 <span class="badge badge-outline badge-info">临床应用与产业化</span></p>
|
||
<p>✓ 全球首个 <span class="badge badge-outline badge-info">干细胞数据管理国际标准</span> IS0 8472-1:2024 发布</p>
|
||
</div>
|
||
<div x-show="tab === 'tech'" class="text-sm space-y-2 text-gray-300">
|
||
<p>✓ <span class="badge badge-outline badge-secondary">iPSC技术</span> 临床治愈1型糖尿病案例出现</p>
|
||
<p>✓ <span class="badge badge-outline badge-secondary">超级干细胞</span> 培育成功，分化能力更强</p>
|
||
<p>✓ <span class="badge badge-outline badge-secondary">干细胞贴片</span> 可无创修复受损心脏</p>
|
||
<p>✓ <span class="badge badge-outline badge-secondary">AI重编程</span> 癌症干细胞，促其自我毁灭</p>
|
||
<p>✓ <span class="badge badge-outline badge-secondary">实验室制成</span> 可移植人类血液干细胞</p>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<!-- Stock tables full width -->
|
||
<div class="col-span-12">
|
||
<div class="glass-card p-6">
|
||
<h2 class="text-2xl font-bold text-cyan-400 mb-4">相关上市公司 | Related Public Companies</h2>
|
||
|
||
<!-- 涨幅异动分析 -->
|
||
<h3 class="text-xl font-semibold text-white mt-6 mb-3">近期异动分析</h3>
|
||
<div class="overflow-x-auto">
|
||
<table class="table table-sm w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>股票代码</th>
|
||
<th>异动日期</th>
|
||
<th>涨跌幅</th>
|
||
<th class="w-2/5">核心逻辑 / 异动原因</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr>
|
||
<td>济高发展</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600807" target="_blank" class="text-cyan-400 hover:underline">600807</a></td>
|
||
<td>2025-11-13</td>
|
||
<td><span class="text-red-400">+9.92%</span></td>
|
||
<td>政策催化“干细胞”主题+山东本地最小市值。子公司艾克韦生物为细胞中试平台提供设备与服务，实质参与中游配套。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>九芝堂</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=000989" target="_blank" class="text-cyan-400 hover:underline">000989</a></td>
|
||
<td>2025-07-03</td>
|
||
<td><span class="text-red-400">+10.06%</span></td>
|
||
<td>政策催化+干细胞管线（aPAP, 脑卒中）进展共振，被视为“低市值创新药补涨标的”。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>吉贝尔</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=688566" target="_blank" class="text-cyan-400 hover:underline">688566</a></td>
|
||
<td>2025-09-01</td>
|
||
<td><span class="text-red-400">+8.87%</span></td>
|
||
<td>参股国内宫血干细胞龙头浙江生创科技，其核心项目在海南博鳌落地，打开干细胞治疗想象空间。</td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
|
||
<!-- 产业链公司 -->
|
||
<h3 class="text-xl font-semibold text-white mt-8 mb-3">产业链核心公司</h3>
|
||
<div class="overflow-x-auto">
|
||
<table class="table table-sm w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>股票代码</th>
|
||
<th class="w-3/5">核心逻辑</th>
|
||
<th>产业链环节</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<!-- 细胞制备 -->
|
||
<tr>
|
||
<td>中源协和</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600645" target="_blank" class="text-cyan-400 hover:underline">600645</a></td>
|
||
<td>国内干细胞产业化龙头，拥有符合GMP标准的细胞制备中心和丰富的临床备案项目。</td>
|
||
<td><span class="badge badge-info badge-outline">细胞制备/存储/应用</span></td>
|
||
</tr>
|
||
<tr>
|
||
<td>泰林生物</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=300813" target="_blank" class="text-cyan-400 hover:underline">300813</a></td>
|
||
<td>为细胞治疗产业提供符合GMP要求的制备装备，属产业链上游“卖铲人”。</td>
|
||
<td><span class="badge badge-info badge-outline">上游装备</span></td>
|
||
</tr>
|
||
<tr>
|
||
<td>开能健康</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=300272" target="_blank" class="text-cyan-400 hover:underline">300272</a></td>
|
||
<td>参股原天生物，提供细胞制备技术、标准化细胞工厂和CDMO服务。</td>
|
||
<td><span class="badge badge-info badge-outline">细胞制备/CDMO</span></td>
|
||
</tr>
|
||
<tr>
|
||
<td>冠昊生物</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=300238" target="_blank" class="text-cyan-400 hover:underline">300238</a></td>
|
||
<td>子公司依托北大邓宏魁教授CiPS/EPS技术，开展生物型人工肝细胞治疗技术研究。</td>
|
||
<td><span class="badge badge-success badge-outline">细胞应用</span></td>
|
||
</tr>
|
||
<!-- 细胞储存 -->
|
||
<tr>
|
||
<td>南京新百</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600682" target="_blank" class="text-cyan-400 hover:underline">600682</a></td>
|
||
<td>子公司齐鲁干细胞是山东省唯一合法的脐带血保存机构，存储业务收入规模大。</td>
|
||
<td><span class="badge badge-warning badge-outline">细胞储存</span></td>
|
||
</tr>
|
||
<tr>
|
||
<td>南华生物</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=000504" target="_blank" class="text-cyan-400 hover:underline">000504</a></td>
|
||
<td>湖南国资旗下，主营干细胞、免疫细胞存储业务。</td>
|
||
<td><span class="badge badge-warning badge-outline">细胞储存</span></td>
|
||
</tr>
|
||
<!-- 细胞应用 -->
|
||
<tr>
|
||
<td>天士力</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600535" target="_blank" class="text-cyan-400 hover:underline">600535</a></td>
|
||
<td>人脐带间充质干细胞注射液用于治疗慢性心力衰竭，已获批临床。</td>
|
||
<td><span class="badge badge-success badge-outline">细胞应用</span></td>
|
||
</tr>
|
||
<tr>
|
||
<td>我武生物</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=300357" target="_blank" class="text-cyan-400 hover:underline">300357</a></td>
|
||
<td>异体间充质干细胞治疗退行性疾病的药物处于临床前研究阶段。</td>
|
||
<td><span class="badge badge-success badge-outline">细胞应用</span></td>
|
||
</tr>
|
||
<tr>
|
||
<td>济民健康</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=603222" target="_blank" class="text-cyan-400 hover:underline">603222</a></td>
|
||
<td>研发管线包括ADSC治疗2型糖尿病、COPD等。</td>
|
||
<td><span class="badge badge-success badge-outline">细胞应用</span></td>
|
||
</tr>
|
||
<tr>
|
||
<td>何氏眼科</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=301103" target="_blank" class="text-cyan-400 hover:underline">301103</a></td>
|
||
<td>已打造干细胞细胞治疗疗法，在角膜干细胞、视网膜干细胞等开展大量研究。</td>
|
||
<td><span class="badge badge-success badge-outline">细胞应用</span></td>
|
||
</tr>
|
||
<tr>
|
||
<td>义翘神州</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=301047" target="_blank" class="text-cyan-400 hover:underline">301047</a></td>
|
||
<td>提供细胞因子等生物试剂，用于干细胞培养和研究。</td>
|
||
<td><span class="badge badge-info badge-outline">上游试剂</span></td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<script>
|
||
// ECharts Initialization
|
||
var chartDom = document.getElementById('marketChart');
|
||
var myChart = echarts.init(chartDom);
|
||
var option;
|
||
|
||
option = {
|
||
backgroundColor: 'transparent',
|
||
tooltip: {
|
||
trigger: 'axis',
|
||
backgroundColor: 'rgba(0, 0, 0, 0.7)',
|
||
borderColor: '#00BFFF',
|
||
textStyle: {
|
||
color: '#E0E0E0'
|
||
},
|
||
formatter: function (params) {
|
||
let result = params[0].name + '年<br/>';
|
||
params.forEach(item => {
|
||
result += item.marker + item.seriesName + ': ' + item.value + (item.seriesName === '全球市场' ? ' 亿美元' : ' 亿元') + '<br/>';
|
||
});
|
||
return result;
|
||
}
|
||
},
|
||
legend: {
|
||
data: ['全球市场 (亿美元)', '中国市场 (亿元)'],
|
||
textStyle: {
|
||
color: '#ccc'
|
||
},
|
||
top: 'bottom'
|
||
},
|
||
grid: {
|
||
left: '3%',
|
||
right: '4%',
|
||
bottom: '15%',
|
||
containLabel: true
|
||
},
|
||
xAxis: {
|
||
type: 'category',
|
||
boundaryGap: false,
|
||
data: ['2024', '2025', '2026', '2027', '2028', '2029', '2030'],
|
||
axisLine: { lineStyle: { color: 'rgba(255, 255, 255, 0.3)' } }
|
||
},
|
||
yAxis: [
|
||
{
|
||
type: 'value',
|
||
name: '亿美元',
|
||
position: 'left',
|
||
axisLine: { show: true, lineStyle: { color: '#00BFFF' } },
|
||
axisLabel: { color: '#00BFFF' },
|
||
splitLine: { lineStyle: { color: 'rgba(255, 255, 255, 0.1)' } }
|
||
},
|
||
{
|
||
type: 'value',
|
||
name: '亿元',
|
||
position: 'right',
|
||
axisLine: { show: true, lineStyle: { color: '#BE46FF' } },
|
||
axisLabel: { color: '#BE46FF' },
|
||
splitLine: { show: false }
|
||
}
|
||
],
|
||
series: [
|
||
{
|
||
name: '全球市场 (亿美元)',
|
||
type: 'line',
|
||
yAxisIndex: 0,
|
||
smooth: true,
|
||
itemStyle: { color: '#00BFFF' },
|
||
lineStyle: {
|
||
width: 2,
|
||
shadowColor: 'rgba(0, 191, 255, 0.5)',
|
||
shadowBlur: 10
|
||
},
|
||
data: [null, 170, 194, 221, 252, 287, 330]
|
||
},
|
||
{
|
||
name: '中国市场 (亿元)',
|
||
type: 'line',
|
||
yAxisIndex: 1,
|
||
smooth: true,
|
||
itemStyle: { color: '#BE46FF' },
|
||
lineStyle: {
|
||
width: 2,
|
||
shadowColor: 'rgba(190, 70, 255, 0.5)',
|
||
shadowBlur: 10
|
||
},
|
||
data: [265, 295, 325, null, null, null, null]
|
||
}
|
||
]
|
||
};
|
||
myChart.setOption(option);
|
||
window.addEventListener('resize', myChart.resize);
|
||
</script>
|
||
</body>
|
||
</html> |